SCRS Welcomes Takeda as Global Impact Partner
May 25, 2023 – The Society for Clinical Research Sites (SCRS) announced today that Takeda has joined the organization as a Global Impact Partner (GIP).
The SCRS GIP program provides industry sponsors, CROs, solution providers and sites the opportunity to directly engage with SCRS and its member community. Takeda will provide input on strategic initiatives for the organization and meaningfully contribute to SCRS events, publications and committees. Through this partnership, Takeda will also gain a deeper understanding of the needs of research sites and contribute to the development of forward-thinking solutions in the clinical research marketplace.
Marisa Rackley, Takeda Head of CSSE, VP, commented, “As Takeda takes on increased ownership of study execution, it is critical that we build and strengthen relationships with clinical trial sites. We are excited to join SCRS as a Global Impact Partner and look forward to working hand-in-hand with sites to improve clinical trial processes with the aim of delivering medicines to patients faster.”
“The Takeda Study Site Engagement team is looking forward to the opportunities to collaborate with our clinical trial sites on their stage. Our hope is that the additional interactions we can achieve via SCRS will increase our understanding of what these sites need to succeed, so as a sponsor we can build lasting, meaningful connections and execute our trials in the most efficient manner,” said Ben Lanning, Takeda’s Head of SSE, Senior Director.
“SCRS is pleased to include Takeda as its newest Global Impact Partner,” said Sean Soth, Senior VP of Global Business Partnerships, SCRS. “With a long history of life science development, one of Takeda’s leading values is putting the patient first. This is a value that SCRS member sites recognize, applaud and share each and every day. Our community looks forward to collaborations with the Takeda team.”
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
About SCRS
Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit MySCRS.org.
